Modality
ADC
MOA
PD-L1i
Target
KIF18A
Pathway
STING
IgAN
Development Pipeline
Preclinical
Jun 2024
→ Apr 2028
PreclinicalCurrent
NCT04338272
1,453 pts·IgAN
2024-06→2028-04·Active
1,453 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-152.0y awayInterim· IgAN
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Active
Catalysts
Interim
2028-04-15 · 2.0y away
IgAN
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04338272 | Preclinical | IgAN | Active | 1453 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |